Emerging therapeutic strategies targeting the p53 pathway, including reactivating mutant p53, inhibiting MYC-driven oncogenesis, and modulating immune responses, offer promising avenues for improving SCLC treatment outcomes. This evidence concerns the gene MYC and small cell lung carcinoma.